Literature DB >> 20553988

Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia.

Maria Kraj1, Joanna Kopeć-Szlęzak, Ryszard Pogłód, Barbara Kruk.   

Abstract

Prospective flow cytometric analysis of antigens expression on bone marrow and peripheral blood plasma cells of 36 plasma cell leukemia (PCL) patients enabled to establish the following immunophenotype of leukemic plasma cell: CD38(++), CD138(+), CD54(+), CD49d(+), CD29(+), CD44(+), CD126(+), CD19(-), CD45(-). In one-third of patients PCL cells express CD56, CD71 and CD117. Expression of CD54 on plasma cells was higher as compared to expression of adhesion molecules CD11a, CD18 and CD11b (p<0.01). Expression of CD18, CD11a, CD11b was lower on bone marrow and higher on peripheral blood cells. In conclusion, impaired expression of adhesion molecules such as CD11a/CD18 or CD56 may explain hematogenic dissemination characterizing PCL.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20553988     DOI: 10.1016/j.leukres.2010.04.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  16 in total

1.  A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.

Authors:  Yasunobu Sekiguchi; Asami Shimada; Mutsumi Wakabayashi; Keiji Sugimoto; Shigeki Tomita; Hiroshi Izumi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ohta; Norio Komatsu; Masaaki Noguchi
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 2.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

Review 3.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

Review 4.  Primary Plasma Cell Leukemia: Identity Card 2016.

Authors:  Pellegrino Musto; Vittorio Simeon; Katia Todoerti; Antonino Neri
Journal:  Curr Treat Options Oncol       Date:  2016-04

5.  Biclonal light chain gammopathy with aberrant CD33 expression in secondary plasma cell leukemia.

Authors:  Michael Gentry; Mark Pettenati; Changlee S Pang
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

6.  Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.

Authors:  Renata Bezdekova; Tomas Jelinek; Romana Kralova; Martin Stork; Petra Polackova; Pavla Vsianska; Lucie Brozova; Jiri Jarkovsky; Martina Almasi; Ivanna Boichuk; Zdenka Knechtova; Miroslav Penka; Ludek Pour; Sabina Sevcikova; Roman Hajek; Lucie Rihova
Journal:  Br J Haematol       Date:  2021-09-09       Impact factor: 8.615

7.  HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.

Authors:  Alessandro Canella; Hector Cordero Nieves; Douglas W Sborov; Luciano Cascione; Hanna S Radomska; Emily Smith; Andrew Stiff; Jessica Consiglio; Enrico Caserta; Lara Rizzotto; Nicola Zanesi; Volinia Stefano; Balveen Kaur; Xiaokui Mo; John C Byrd; Yvonne A Efebera; Craig C Hofmeister; Flavia Pichiorri
Journal:  Oncotarget       Date:  2015-10-13

8.  Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.

Authors:  Alexey Zatula; Aida Dikic; Celine Mulder; Animesh Sharma; Cathrine B Vågbø; Mirta M L Sousa; Anders Waage; Geir Slupphaug
Journal:  Oncotarget       Date:  2017-03-21

Review 9.  Practical management and assessment of primary plasma cell leukemia in the novel agent era.

Authors:  A Visram; A Suska; A Jurczyszyn; W I Gonsalves
Journal:  Cancer Treat Res Commun       Date:  2021-06-08

10.  The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160).

Authors:  Sung-Hoon Jung; Je-Jung Lee; Kihyun Kim; Cheolwon Suh; Dok Hyun Yoon; Chang-Ki Min; Sang Kyun Sohn; Chul Won Choi; Ho Sup Lee; Hyo Jung Kim; Ho-Jin Shin; Soo-Mee Bang; Sung-Soo Yoon; Seong Kyu Park; Ho-Young Yhim; Min Kyoung Kim; Jae-Cheol Jo; Yeung-Chul Mun; Jae Hoon Lee; Jin Seok Kim
Journal:  Oncotarget       Date:  2017-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.